Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Annovis Bio, Inc. Common Stock (NY: ANVS )

5.010 +0.550 (+12.33%)
Official Closing Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 277,758
Open 4.430
Bid (Size) 4.920 (1)
Ask (Size) 5.160 (1)
Prev. Close 4.460
Today's Range 4.383 - 5.110
52wk Range 4.210 - 22.49
Shares Outstanding 13,797,242
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Committed to Ensuring Highest Standards in Continued Buntanetap Trials
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Eyes Clear Path Forward for Buntanetap
Via Investor Brand Network

Performance

YTD
-73.53%
-73.53%
1 Month
-29.14%
-29.14%
3 Month
-37.38%
-37.38%
6 Month
-17.73%
-17.73%
1 Year
-67.36%
-67.36%

More News

Read More
Annovis Bio Inc. (NYSE: ANVS) Showcases 2024 Achievements and Strategic Vision in Year-End Investor Webcast
Via Investor Brand Network
New Staging System Could Forecast How Quickly Parkinson’s Might Progress After Diagnosis
Via Investor Brand Network
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace
From InvestorBrandNetwork (IBN)
Via GlobeNewswire
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) CEO Highlights Innovations in Neurodegenerative Drug Development on Today’s Marketplace
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) CEO Shares Insight on Breakthrough Drug Showing Promise for Neurodegenerative Diseases
Via Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) to Present Recent Achievements and 2025 Strategic Outlook During Upcoming Live Investor Webcast
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Share Clinical and Strategic Updates
Via Investor Brand Network
Research Suggests Cancer Survivors are Less Prone to Alzheimer’s Development
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Paving the Way for NDA Submission
Via Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Concludes Q3 with Strategic Milestones and FDA-Cleared Phase 3 Program for Alzheimer’s Disease
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. CEO to Showcase Buntanetap’s Dual Benefits for Alzheimer’s and Parkinson’s at NIA Workshop
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. Advances Alzheimer’s Phase 3 Trials with Strong FDA Support and Financial Backing
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
BioMedNewsBreaks — Annovis Bio Inc. Strengthens Clinical Research Team with Appointment of Senior Clinical Scientist
Via Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Highlights Buntanetap Results at 17th Clinical Trials on Alzheimer’s Disease (‘CTAD’) 2024 Conference
Via Investor Brand Network
Study Explores How Antimicrobials Impact the Risk of Developing Parkinson’s Disease
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) CEO Details Promising Phase 3 Path for Alzheimer’s Treatment on The BioMedWire Podcast
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Moving Closer to Providing Much-Needed Treatments to Patients
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Annovis Bio Inc. (NYSE: ANVS) Receives FDA Clearance to Initiate Pivotal Phase 3 Alzheimer’s Studies, Paving the Way for NDA Filings
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Present Key Alzheimer’s Research at CTAD Conference in Madrid
Via Investor Brand Network
Analysis of Medical Records Repeatedly Links Viruses to Alzheimer’s
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Receives FDA Clearance for Pivotal Phase 3 Alzheimer’s Trial, Launch Set for Early 2025
Via Investor Brand Network
Exposures Product Safety
Annovis Bio Inc. (NYSE: ANVS) Seeking to Strengthen Intellectual Property Portfolio, Protecting Multifaceted Approach for Treatment of Neurodegenerative Diseases
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via Investor Brand Network
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.